Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-04-21 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2025 年第一季度报告" which translates to "2025 First Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the period January to March 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It is unaudited but contains substantive financial data and management commentary on financial results and business trends. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-21 Chinese
关于召开2025年第一次临时股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2025 first extraordinary general meeting of shareholders (临时股东大会通知公告) for Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items related to stock option incentive plans, and procedural information for shareholders. There is no financial data or report content included, only the announcement of the meeting and its agenda. The document is under 5,000 characters and serves as a formal meeting notice rather than a report or results announcement. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2025-04-21 Chinese
关于独立董事公开征集表决权公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement by independent directors soliciting proxy voting rights from shareholders for an upcoming extraordinary general meeting (EGM) scheduled for May 8, 2025. It details the agenda items related to a stock option incentive plan and the procedures for shareholders to authorize voting rights to the independent directors. The document does not contain financial statements or results but is focused on the solicitation of voting rights and proxy instructions for the EGM. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it is about the collection of voting rights and proxy solicitation for shareholder voting at a meeting. The document length is under 5,000 characters and is not a report publication announcement or a full report. Therefore, the best classification is DVA with high confidence.
2025-04-21 Chinese
中信证券股份有限公司关于山西锦波生物医药股份有限公司2025年股票期权激励计划（草案）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding a 2025 stock option incentive plan for Shanxi Jinbo Biopharmaceutical Co., Ltd. It is a detailed report discussing the stock option plan, including definitions, assumptions, main content of the plan, allocation, pricing, conditions, and the independent financial advisor's opinions on the plan's compliance, feasibility, and fairness. The document is lengthy (15,000 characters) and contains substantive financial and operational details about the stock option incentive plan. It is not a simple announcement or a brief summary but a comprehensive advisory report. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through stock option incentives. It is not an Annual Report, Audit Report, or Management Report, nor is it a regulatory filing or announcement. Therefore, the classification is CAP with high confidence.
2025-04-21 Chinese
监事会关于公司2025年股票期权激励计划（草案）的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board opinion on the company's 2025 stock option incentive plan draft. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and procedural correctness. It does not contain financial statements or results, nor is it an announcement of a meeting or voting results. It is a regulatory compliance and internal governance-related document concerning management incentives. This fits best under Regulatory Filings (RNS) as it is a compliance announcement that does not fit other specific categories like management changes or remuneration reports.
2025-04-21 Chinese
2025年股票期权激励计划首次授予激励对象名单
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding the initial grant list of stock option incentives under the 2025 stock option incentive plan. It lists the names, positions, and stock option quantities allocated to various employees and directors. The content focuses on the allocation of stock options as part of an incentive plan, which is a capital-related update. There is no indication that this is a full financial report, earnings release, or management discussion. The document is not a report publication announcement or a certification. It is an update on the company's capital structure related to stock options granted to employees and executives. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is short but contains substantive information about the stock option grant, not just an announcement of a report.
2025-04-21 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.